Baird Financial Group Inc. Sells 49,243 Shares of DexCom, Inc. $DXCM

Baird Financial Group Inc. reduced its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 637,765 shares of the medical device company’s stock after selling 49,243 shares during the period. Baird Financial Group Inc. owned 0.16% of DexCom worth $55,671,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Andra AP fonden purchased a new stake in DexCom in the 2nd quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of DexCom in the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT bought a new position in shares of DexCom in the first quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom during the second quarter valued at approximately $45,000. Finally, Anderson Financial Strategies LLC bought a new stake in DexCom during the first quarter worth $37,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DXCM. UBS Group reduced their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Weiss Ratings reissued a “sell (d+)” rating on shares of DexCom in a research report on Monday. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 price target on shares of DexCom in a research note on Monday, November 3rd. TD Cowen lowered their price target on shares of DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, Evercore ISI began coverage on DexCom in a research note on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average price target of $87.27.

Insider Transactions at DexCom

In related news, Director Richard Alexander Collins sold 2,906 shares of the company’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the transaction, the director directly owned 35,088 shares in the company, valued at approximately $2,071,946.40. The trade was a 7.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 7,866 shares of company stock valued at $448,177. Insiders own 0.32% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $65.25 on Friday. The stock’s 50-day simple moving average is $64.00 and its two-hundred day simple moving average is $75.31. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The firm has a market capitalization of $25.45 billion, a P/E ratio of 36.25, a P/E/G ratio of 1.39 and a beta of 1.51. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the business posted $0.45 earnings per share. DexCom’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.